This company listing is no longer active
CinCor Pharma Balance Sheet Health
Financial Health criteria checks 6/6
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$522.50m |
| Equity | US$518.94m |
| Total liabilities | US$10.18m |
| Total assets | US$529.12m |
Recent financial health updates
Here's Why We're Not Too Worried About CinCor Pharma's (NASDAQ:CINC) Cash Burn Situation
Nov 06
We Think CinCor Pharma (NASDAQ:CINC) Can Afford To Drive Business Growth
Jul 23We're Hopeful That CinCor Pharma (NASDAQ:CINC) Will Use Its Cash Wisely
Apr 08Recent updates
Here's Why We're Not Too Worried About CinCor Pharma's (NASDAQ:CINC) Cash Burn Situation
Nov 06CinCor Pharma prices upsized stock and pre-funded warrants offering
Aug 11CinCor Pharma says last patient randomized in phase 2 trial for baxdrostat to treat hypertension
Jul 26We Think CinCor Pharma (NASDAQ:CINC) Can Afford To Drive Business Growth
Jul 23We're Hopeful That CinCor Pharma (NASDAQ:CINC) Will Use Its Cash Wisely
Apr 08CinCor: 2022 Data Catalysts Will Derisk The Stock
Apr 07Financial Position Analysis
Short Term Liabilities: CINC's short term assets ($529.0M) exceed its short term liabilities ($10.2M).
Long Term Liabilities: CINC has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CINC is debt free.
Reducing Debt: CINC has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CINC has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CINC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 60.7% each year
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/25 10:49 |
| End of Day Share Price | 2023/02/23 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CinCor Pharma, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael DiFiore | Evercore ISI |
| Madhu Kumar | Goldman Sachs |
| Yuchen Ding | Jefferies LLC |